PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

US neurologists agree on protocols for treatment of infantile spasms

Guidelines aid pediatricians with early diagnosis to improve long-term prognosis

2010-09-04
(Press-News.org) Researchers from across the U.S., as part of the Infantile Spasms Working Group (ISWG), established guidelines for the diagnosis and treatment of infantile spasms (IS). The goal of the ISWG is to improve patient outcomes by creating protocols that educate pediatricians on early diagnosis and treatment options. Full details of this study appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Infantile spasms—known also as West syndrome and named after Dr. William James West who provided the first account of the disease in his 1841 medical article—is a rare epileptic disorder that typically presents in infants between 3 and 7 months of age.

Symptoms of IS include spasms of the limbs and trunk (extending or stiffening of the arms, legs, neck or trunk) that occur in clusters, an electroencephalography (EEG) pattern of hypsarrhythmia, and psychomotor delay or arrest.

The IS incidence ranges from 2 to 3.5 per 10,000 live births, occurring in more boys than girls (60:40). Approximately 90% of all IS cases occur during the first year of life, but can affect children up to the age of 4. While some cases have unknown cause (cryptogenic IS), many experts cite tuberous sclerosis (benign growth of brain tumors) and lack of oxygen to the baby at birth as common causes of symptomatic IS.

As part of their investigation, the ISWG (led by John Pellock, M.D.) examined scores of related studies and reviewed current clinical practice. The goal was to establish criteria that target early diagnosis, timely treatment options, and support IS patients and their families. Dr. Pellock, commenting on the agreed protocols, said "We strongly recommend broad clinical evaluation, including: detailed clinical neurophysiology; continued use of vigabatrin (VGB) or adrenocorticotropic hormone (ACTH) as first-line treatment to suppress clinical spasms and abolish hypsarrhythmic EEG; a timely assessment of treatment efficacy (regardless of chosen medication), with prompt therapy modification to avoid serious adverse events and with a particular goal of establishing an 'all-or-none' response where effective IS treatment should produce cessation of spasms and resolution of hypsarrhythmia on EEG."

To establish an IS diagnosis, a clinical evaluation is needed whereby doctors begin with a complete history and physical examination of the patient. Spasms observed by parents or physicians may vary from a cluster of as few as 2 to more than 100, lasting from less than 1 minute to more than 10 minutes. A full EEG evaluation is conducted to uncover any hypsarrhythmic pattern characterizing IS. Next, the etiologic diagnosis is made, aided by MRI, to understand the cause of the disorder. Such a diagnosis will aid in establishing the appropriate treatment strategy. "Following the completion of the history, physical, and neurological examinations, as well as EEG and MRI analysis, roughly 70% of patients will have an established diagnosis without the need for extensive metabolic testing" noted the ISWG team. "This saves valuable time to initiation of treatment and reduces evaluation costs."

There was consensus in the ISWG that use of ACTH is effective as first-line therapy for IS. However, the team believed there was insufficient evidence to define precisely the optimum ACTH dose and duration of treatment for IS; in general, short duration was preferred (i.e., approximately 2 weeks followed by taper). The ISWG also agreed on the efficacy of VGB as a first-line treatment option, with a dose of 50 mg/kg/day up to 100-150 mg/kg/ day in patients requiring escalation. Since prior studies have established a risk of visual field loss with VGB treatment, the ISWG suggested that infants who respond to this therapy may continue for 6-9 months, with continued ophthalmic evaluation.

Raili Riikonen, M.D., from Children's Hospital at the University of Kuopio in Finland, said in her commentary, "The goals of the ISWG are certainly worthwhile, but it should be appreciated that treatment approaches differ in Europe from the protocols described in this U.S. perspective." In Europe there are differing opinions on first-line treatment options for IS. After two weeks of VGB therapy, seizure freedom was seen in 26% of patients (Granström et al., 1999), 23% of patients (Elterman et al., 2000), and 54% of patients (Lux et al., 2004). In the first two of these studies, the number of IS patients who were seizure-free increased to roughly 65% after 3 months. "These data suggested the response with VGB comes later than with ACTH," Dr. Riikonen stated.

In Japan, treatment strategies for IS also differ from the recommended U.S. protocols. "The dosage of ACTH administered in Japan is strikingly different than prescribed amounts in the U.S.," commented Yukio Fukuyama, M.D., Ph.D., from the Child Neurology Institute in Tokyo, Japan in his commentary on the study by Pellock et al. A 6-month old infant with 8 kg body weight and 0.4 m2 body surface, would be administered a daily dose of ACTH of 60 IU/day (0.6 mg/day) in the U.S. versus 5 IU/day (0.05 mg/day) in Japan. The dosage difference between the U.S. and Japan is likely due to the different preparation forms (simple natural vs. prolonged synthetic). "Despite this large difference in dosage, the rate of seizure disappearance and EEG amelioration appears to be similar. Since the introduction of this low dosage scheme in Japan, it has been rare to observe serious side effects of ACTH (e.g., obesity, hypertension, hypertrichosis, electrolyte imbalance, manifest immunodepression, cardiac dilation, brain shrinkage on CT/MRI) in our daily practice," noted Dr. Fukuyama. VGB is currently not commercially available in Japan.

Oliver Dulac, M.D. and colleagues stated in their commentary, "Pellock et al. provide an excellent overview of IS in the form of a consensus report by a reliable panel of experts." This European team emphasized that IS is not a disease per se, but a common denominator of several conditions, mainly determined by etiology. Patients with different IS etiologies experience different disease courses, requiring different and specific treatment strategies and durations. Both Pellock et al. and Dulac et al. agree that length of IS therapy is one of the most challenging current questions in effectively and safely treating IS patients. VGB treatment, in particular, needs a balanced approach to curb retinal toxicity. "Patients with no cortical lesion (e.g. Down syndrome, leukodystrophy, or cryptogenic cases) usually require no chronic treatment following the control of spasms—ACTH treatment may be stopped after only one month, and VGB after 6 months," said Dr. Dulac.

While IS is a rare condition, the outcomes for patients with the disorder include higher mortality, ongoing development of additional seizure disorders as the patient matures, and often severe cognitive and developmental delay. A 2003 study by Hrachovy and Frost reviewed 67 published studies, with an average follow-up period of 31 months, and found only 16% of patients with IS had normal development. Additional studies indicated that severe learning difficulties may be present in 70% to 90% of IS patients. An IS study in an Atlanta birth cohort (1975�) found that 15% of patients died by age 11 and 35% died by age 25 (Trevathan et al., 1999).

"The establishment of an IS patient registry, and the development of a continuum of care for patients with this disorder are critical for improving outcomes," added Dr. Pellock. The ISWG suggested the need for a comprehensive approach for optimal management of children with IS, including access to and evaluation by a variety of professionals, including child neurologists, pediatricians, psychiatrists, rehabilitation services (physical, occupational and speech therapy), nurses, vocational rehabilitation counselors, neuropsychologists, social workers, and pharmacists. "Further studies are needed to determine ideal treatment strategies for IS; carefully controlled comparative studies or patient registries will allow a standard format for gathering important clinical data (e.g. IS recurrence rates, administered therapy details, developmental outcomes) from a large patient sample," concluded Dr. Pellock.

INFORMATION: This study is published in Epilepsia. Media wishing to receive a PDF of the articles may contact healthnews@wiley.com.

Full Citations:

Article: "Historical Infantile spasms: A U.S. consensus report." John M. Pellock, Richard Hrachovy, Shlomo Shinnar, Tallie Z. Baram, David Bettis, Dennis J. Dlugos, William D. Gaillard, Patricia A. Gibson, Gregory L. Holmes, Douglas R. Nordli, Christine O'Dell, W. Donald Shields, Edwin Trevathan, and James W. Wheless. Epilepsia; Published Online: July 1, 2010 (DOI: 10.1111/j.1528-1167.2010.02657.x). Print Issue Date: October 2010.

Commentary: "A European perspective – Comments on Infantile Spasms: 2009 U.S. Update." Raili Riikonen. Epilepsia; Published Online: September 3, 2010 (DOI: 10.1111/j.1528-1167.2010.02704.x). Print Issue Date: October 2010.

Commentary: "The Japanese scheme of ACTH therapy in West syndrome." Yukio Fukuyama. Epilepsia; Published Online: September 3, 2010 (DOI: 10.1111/j.1528-1167.2010.02718.x). Print Issue Date: October 2010.

Commentary: "The Infantile spasms: toward a selective diagnostic and therapeutic approach." Oliver Dulac, Thomas Bast, Bernardina Dalla, Eija Gaily, Brian Neville. Epilepsia; Published Online: September 3, 2010 (DOI: 10.1111/j.1528-1167.2010. 02657.x). Print Issue Date: October 2010.

Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. For more information, please visit http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1528-1167

Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.



ELSE PRESS RELEASES FROM THIS DATE:

Rochester leads international effort to improve muscular dystrophy treatment

2010-09-04
A large international study aimed at improving the care of muscular dystrophy patients worldwide is being launched by physicians, physical therapists, and researchers at the University of Rochester Medical Center. Neurologist Robert "Berch" Griggs, M.D., is heading the study of treatments for Duchenne muscular dystrophy, the most common form of the disease that affects children. The condition, which affects boys almost exclusively, progresses rapidly. Boys' symptoms start when they are toddlers; untreated, they end up in a wheelchair before they become teenagers. With ...

Satellite data reveal why migrating birds have a small window to spread bird flu

2010-09-04
In 2005 an outbreak of the H5N1 'bird flu' virus in South East Asia led to widespread fear with predictions that the intercontinental migration of wild birds could lead to global pandemic. Such fears were never realised, and now research published in the British Ecological Society's Journal of Applied Ecology reveals why the global spread of bird flu by direct migration of wildfowl is unlikely but also provides a new framework for quantifying the risk of avian-borne diseases. The highly pathogenic H5N1 bird flu virus is primarily a disease of poultry, often resulting ...

First clinical trials successfully completed on potent new hepatitis C drug

2010-09-04
The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed. Completion of the initial phase (phase 1a) of trials of INX-189, discovered and first prepared by researchers at Cardiff University's Welsh School of Pharmacy in 2008, means the chances of it becoming an approved medicine have significantly improved. Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation ...

Earth from space: Giant iceberg enters Nares Strait

Earth from space: Giant iceberg enters Nares Strait
2010-09-04
ESA's Envisat satellite has been tracking the progression of the giant iceberg that calved from Greenland's Petermann glacier on 4 August 2010. This animation shows that the iceberg, the largest in the northern hemisphere, is now entering Nares Strait – a stretch of water that connects the Lincoln Sea and Arctic Ocean with Baffin Bay. The Petermann glacier in northern Greenland is one of the largest of the country's glaciers – and until August it had a 70 km tongue of floating ice extending out into the sea. The glacier regularly advances towards the sea at about 1 km ...

Rutgers-Camden professor engineers E. coli to produce biodiesel

2010-09-04
CAMDEN — One mention of E. coli conjures images of sickness and food poisoning, but the malevolent bacteria may also be the key to the future of renewable energy. Desmond Lun, an associate professor of computer science at Rutgers University–Camden, is researching how to alter the genetic makeup of E. coli to produce biodiesel fuel derived from fatty acids. "If we can engineer biological organisms to produce biodiesel fuels, we'll have a new way of storing and using energy," Lun says. Creating renewable energy by making fuels, like making ethanol out of corn, has been ...

Americans struggle with long-term weight loss

2010-09-04
Only about one in every six Americans who have ever been overweight or obese loses weight and maintains that loss, according to Penn State College of Medicine researchers. While that number is larger than most weight-loss clinical trials report, the majority of Americans are still unable to lose weight and keep it off. Identifying those who lose weight and successfully maintain that loss may aid health professionals in developing approaches to help others maintain weight loss, the researchers say. Two-thirds of the United States adult population is overweight, defined ...

Publication of World Health Report 2000 'an act of remarkable courage,' says school expert

2010-09-04
Ten years on, Martin McKee reflects on report placed health system performance rankings firmly on political agenda. Martin McKee, Professor of European Health at the London School of Hygiene & Tropical Medicine has contributed one of three commentaries appearing today in the journal Health Policy and Planning, each of which take a different perspective on the World Health Report 2000 on health systems (WHR2000). It is ten years since the publication of WHR2000, a controversial document which many at the time believed had been published prematurely, and which introduced ...

GOES-13 satellite sees Hurricane Earl's clouds covering the US Northeast

GOES-13 satellite sees Hurricane Earls clouds covering the US Northeast
2010-09-04
Hurricane Earl lashed the North Carolina coast last night and this morning, September 3, and is now headed for Cape Cod, Massachusetts. This morning's image from the GOES-13 satellite saw Hurricane Earl's clouds covering most of the northeastern U.S. The Geostationary Operational Environmental Satellite known as GOES-13 captured an image of Hurricane Earl at 7:32 a.m. EDT this morning, September 3. The image clearly showed a huge Hurricane Earl northeast of North Carolina with cloud cover stretching over the northeastern U.S. A disorganized Fiona was also seen southeast ...

NASA hurricane researchers eye Earl's eye

NASA hurricane researchers eye Earls eye
2010-09-04
Hurricane Earl, currently a Category Two storm on the Saffir-Simpson scale with maximum sustained winds of 100 knots (115 miles per hour), continues to push relentlessly toward the U.S. East Coast, and NASA scientists, instruments and spacecraft are busy studying the storm from the air and space. Three NASA aircraft carrying 15 instruments are busy criss-crossing Earl as part of the agency's Genesis and Rapid Intensification Processes mission, or GRIP, which continues through Sept. 30. GRIP is designed to help improve our understanding of how hurricanes such as Earl form ...

AgriLife research hibiscus breeder comes up with the blue

AgriLife research hibiscus breeder comes up with the blue
2010-09-04
VERNON -- Dr. Dariusz Malinowski is seeing blue, and he is very excited. For four years, Malinowski, an AgriLife Research plant physiologist and forage agronomist in Vernon, has been working with collaborators Steve Brown of the Texas Foundation Seed and Dr. William Pinchak and Shane Martin with AgriLife Research on a winter-hardy hibiscus breeding project. The project was first a private hobby of the inventors and became a part of the strategic plan of the Texas AgriLife Research and Extension Center at Vernon in 2009. The flower commercialization is a part ...

LAST 30 PRESS RELEASES:

Wrong trees in the wrong place can make cities hotter at night, study reveals

New gene therapy reverses heart failure in large animal model

Young children less likely than adults to see discrimination as harmful

Tiny poops in the ocean may help solve the carbon problem

Study offers insight into chloroplast evolution

Advancing the synthesis of two-dimensional gold monolayers

Human disruption is driving ‘winner’ and ‘loser’ tree species shifts across Brazilian forests

A novel heme-model compound that treats lethal gas poisoning

Shape-changing device helps visually impaired people perform location task as well as sighted people - EMBARGO: Tuesday 10 December (10:00 UK time)

AI predicts that most of the world will see temperatures rise to 3°C much faster than previously expected

Second round of FRONTIERS Science Journalism Residency Program awards grants to ten journalists

The inequity of wildfire rescue resources in California

Aerosol pollutants from cooking may last longer in the atmosphere – new study

Breakthrough in the precision engineering of four-stranded β-sheets

Family income predicts adult problems more than neighborhood poverty

Leading stress expert Ron de Kloet on hormone's dual nature: From protection to harm

Almost half of young vapers are able to stop with quitline help

After a divisive election, most U.S. adults ready to avoid politics this holiday

Food insecurity in LA County remains well above national average, despite slight decline

People with a positive attitude are built differently

AML, sickle cell disease research among highlights of UC ASH abstracts

Dozens of presentations advance multiple myeloma research at the 2024 American Society for Hematology (ASH) meeting

ASH 2024: Study shows that genetic mutations accumulate in smokers with myelodysplastic syndromes and worsen outcomes

Nature inspires self-assembling helical polymer

Could US-style summer holiday programs boost Aussie kids’ health?

Towards safer, higher performance batteries through network topology optimization

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

Toxoplasma gondii parasite uses unconventional method to make proteins for evasion of drug treatment

US e-scooter/e-bike injuries have tripled since 2019, fuelled by alcohol/substance use

Cost stops 1 in 6 US adults with asthma from taking meds as prescribed, study suggests

[Press-News.org] US neurologists agree on protocols for treatment of infantile spasms
Guidelines aid pediatricians with early diagnosis to improve long-term prognosis